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Identifies Immune
Players Involved in
Allograft RejectionA Call for Precision MedicineWe read with interest about the use of quantitative
multiplex immunofluorescence (QmIF) methodology
(1), which found significantly increased programmed
death-ligand 1 (PD-L1)-positive, forkhead box P3
(FoxP3)-positive, and cluster of differentiation 68
(CD68)-positive cells suppressed in clinically evident
rejections, whereas PD-L1-positive, FoxP3-positive,
and cluster of differentiation 68-positive cell
proportions were significantly higher in “never-
rejection” than in “future-rejection.” Peyster et al. (1)
suggest that in situ immune players regulate the
severity of cardiac allograft rejection (CAR). Con-
ventional study of CAR detection involves the iden-
tification and quantification of basophilic immune
cells on hematoxylin and eosin-stained slides by us-
ing endomyocardial biopsy (EMB), which provides
few pathogenic insights into both immune cells and
individual mechanisms of rejection. In 2005, expert
panels required a more detailed characterization of
the inflammatory infiltrate in order to have a clini-
cally relevant framework useful for discovering pa-
tients with progressive CAR (2). To date, there has
been limited application of tissue-level immune
phenotyping in transplanted heart tissues. The au-
thors performed useful in situ identification and
quantification of CD3, CD8, CD68, FoxP3, and PD-L1,
which were selected from a rejection panel of ani-
mal models and renal transplantation due to limited
research in transplanted heart tissues. Only 33 EMB
samples completed the study analysis: 22 had low
International Society for Heart and Lung Trans-
plantation (ISHLT) grades of 1R and 0R, and 11 had
high ISHLT grades of 2R and 3R (2). First, data must
be considered in the setting of the limited sample
size. Second, it is well known that discordantly high
ISHLT grade designations are uncertain because it is
standard practice for all high ISHLT grade biopsyevents to receive some form of altered immunosup-
pression regardless of the presence of altered clinical
data. Third, the most interesting findings support the
existence of different “immunobiologies” in com-
parison to concordantly high ISHLT grade cases. This
concept is not entirely new because the presence of
distinct phenotypes with distinct fates was proposed
in 2003 (3). On the other hand, the relatively high rate
of a technical failure of QmIF analysis (26% of EMB) is
a real concern in common clinical practice, but as the
authors recognized, “it may reflect our dependence
on residual material following routine clinical pro-
cessing and the 6- to 12-year interval between EMB
sampling and QmIF analysis” (1). Because of intrinsic
limitations of the study and future reorganization of
costs for the health care system due to the
emergent coronavirus 2019 (COVID-19) pandemic,
Peyster et al. (1) performed a valuable study of path-
ogenesis of clinical interest in the surveillance of CAR.
Additionally, it would be interesting to analyze their
data also in correlation to human leukocyte antigen-
DR isotype (HLA-DR) matching at the time of trans-
plantation, because this index may influence out-
comes (4). Nevertheless, cost rationing is an inevitable
occurrence where the potential demand for effective
high-cost techniques will exceed supply. Despite this
rather harmful consideration, the future need is to
investigate prospectively whether integration of
EMB with tissue (1) and liquid biopsy (5) could act
synergistically to form a novel precision
medicine paradigm (5) leading to the optimized man-
agement of patients undergoing heart trans-
plantation.*Claudio Napoli, MD, PhD
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A Call for Precision MedicineWe appreciate the interest shown by Dr. Napoli and
colleagues in our recent publication in JACC: Basic to
Translational Science. We also appreciate their clear
recognition of the need for improved biological
characterization of transplanted endomyocardial bi-
opsy tissues, as well as their appreciation of the in
situ methodology we used in our work. Their letter
raises several important points which we address in
this response.
In our publication, approximately one-fourth of
cases failed technical quality control. There were
several reasons for this, some of which are mentioned
in our paper (e.g., sample age), but other more tech-
nical factors are likely to improve with further expe-
rience and optimization. For example, the automated
quantitative multiplex immunofluorescence (QmIF)
staining workflow had not previously been applied to
samples of heart tissue, and the default temperature
of a heating step used for most tissues caused cov-
erslips to become loose in heart tissues and created
artifacts. Issues like this are relatively easily
addressed once identified, and we expect a higher
quality control pass rate moving forward.
The second point by Dr. Napoli and colleagues refers
to the difficulty in determining if a high-grade
asymptomatic case is truly “discordant” or the devel-
opment of overt graft dysfunction is avoided by early
treatment. It is true that the widespread convention oftreating high-grade endomyocardial biopsy tissuewith
augmented immunosuppression based on histology
alone makes it difficult to control for this potential
confounder in retrospective investigations. Never-
theless, the clear differences in in situ immune profiles
between high-grade endomyocardial biopsies with
and without evidence of graft dysfunction and much
higher expression of the anti-inflammatory mediators
PD-L1 and FoxP3 in the clinically silent cases suggests
that there are real biological differences between these
groups. Although this cannot be proven conclusively
until a prospective investigation is performed, it is
compelling circumstantial evidence.
Finally, Dr. Napoli and colleagues discuss the issue
of cost containment in the context of advanced
diagnostic approaches such as QmIF. Although cost
considerations may influence adoption of new tech-
nologies, if QmIF substantially improves the accuracy
of rejection diagnosis and aids in risk stratification,
then initial assay costs may be offset by reduced
complications and improved patient outcomes. In
low-risk populations, minimizing low-yield proced-
ures saves money, especially if associated with re-
ductions in excess immunosuppression which can
predispose patients to iatrogenic injury. In high-risk
populations, more aggressive surveillance, preven-
tion, and treatment strategies can reduce hospitali-
zations and major complications and potentially
reduce cost. Whether this potential will be realized
will, of course, require further investigation.Eliot G. Peyster, MD, MSc
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